Affymax has announced results from a Phase II clinical trial of Hematide in
patients with anemia due to chronic kidney disease (CKD). Hematide is a novel
peptide-based drug candidate designed to stimulate the production of red blood
The trial is a randomized, double-blind, placebo-controlled, dose-escalation study evaluating a single intravenous injection of Hematide administered to patients with CKD. The study found that Hematide was well-tolerated and demonstrated potent and sustained erythropoietic activity of the same magnitude as that observed in healthy volunteers.